Novel Intriguing Strategies Attenuating to Sarcopenia by Sakuma, Kunihiro & Yamaguchi, Akihiko
Hindawi Publishing Corporation
Journal of Aging Research
Volume 2012, Article ID 251217, 11 pages
doi:10.1155/2012/251217
Review Article
Novel IntriguingStrategies Attenuating to Sarcopenia
KunihiroSakuma1 andAkihikoYamaguchi2
1Research Center for Physical Fitness, Sports and Health, Toyohashi University of Technology, 1-1 Hibarigaoka, Tenpaku-cho,
Toyohashi 441-8580, Japan
2School of Dentistry, Health Sciences University of Hokkaido, Kanazawa, Ishikari-Tobetsu, Hokkaido 061-0293, Japan
Correspondence should be addressed to Kunihiro Sakuma, ksakuma@las.tut.ac.jp
Received 29 July 2011; Accepted 25 November 2011
Academic Editor: Olivier Gu´ erin
Copyright © 2012 K. Sakuma and A. Yamaguchi. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Sarcopenia, the age-related loss of skeletal muscle mass, is characterized by a deterioration of muscle quantity and quality leading
to a gradual slowing of movement, a decline in strength and power, increased risk of fall-related injury, and, often, frailty. Since
sarcopenia is largely attributed to various molecular mediators aﬀecting ﬁber size, mitochondrial homeostasis, and apoptosis,
the mechanisms responsible for these deleterious changes present numerous therapeutic targets for drug discovery. Resistance
training combined with amino acid-containing supplements is often utilized to prevent age-related muscle wasting and weakness.
In this review, we summarize more recent therapeutic strategies (myostatin or proteasome inhibition, supplementation with
eicosapentaenoic acid (EPA) or ursolic acid, etc.) for counteracting sarcopenia. Myostatin inhibitor is the most advanced research
with a Phase I/II trial in muscular dystrophy but does not try the possibility for attenuating sarcopenia. EPA and ursolic acid
seem to be eﬀective as therapeutic agents, because they attenuate the degenerative symptoms of muscular dystrophy and cachexic
muscle. The activation of peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) in skeletal muscle by exercise
and/or unknown supplementation would be an intriguing approach to attenuating sarcopenia. In contrast, muscle loss with age
may not be inﬂuenced positively by treatment with a proteasome inhibitor or antioxidant.
1.Introduction
Skeletal muscle contractions power human body movements
and are essential for maintaining stability. Skeletal muscle
tissue accounts for almost half of the human body mass
and, in addition to its power-generating role, is a crucial
factor in maintaining homeostasis. Given its central role in
human mobility and metabolic function, any deterioration
in the contractile, material, and metabolic properties of
skeletal muscle has an extremely important eﬀect on human
health. Aging is associated with a progressive decline of
muscle mass, quality, and strength, a condition known
as sarcopenia [1]. The term sarcopenia, coined by I. H.
Rosenberg, originates from the Greek words sarx (ﬂesh) and
penia(loss).Althoughthistermisappliedclinicallytodenote
loss of muscle mass, it is often used to describe both a set of
cellular processes (denervation, mitochondrial dysfunction,
inﬂammatory and hormonal changes) and a set of outcomes
such as decreased muscle strength, decreased mobility and
function [2], increased fatigue, a greater risk of falls [3],
and reduced energy needs [4]. In addition, reduced muscle
mass in aged individuals has been associated with decreased
survival rates following critical illness [5]. Estimates of the
prevalence of sarcopenia range from 13% to 24% in adults
over60yearsofagetomorethan50%inpersonsaged80and
older [2]. The estimated direct healthcare costs attributable
to sarcopenia in the United States in 2000 were $18.5 billion
($10.8 billion in men and $7.7 billion in women), which
represented about 1.5% of total healthcare expenditures for
that year [6]. Therefore, age-related losses in skeletal muscle
mass and function present an extremely important current
and future public health issue.
Lean muscle mass generally contributes up to ∼50% of
total body weight in young adults but declines with aging
to be 25% at 75–80 yr old [7, 8] .T h el o s so fm u s c l em a s s
is typically oﬀset by gains in fat mass. The loss of muscle
mass is most notable in the lower limb muscle groups,
with the cross-sectional area of the vastus lateralis being2 Journal of Aging Research
reduced by as much as 40% between the age of 20 and 80
yr [9]. On a muscle ﬁber level, sarcopenia is characterized
by speciﬁc type II muscle ﬁber atrophy, ﬁber necrosis, and
ﬁber-type grouping [9–13]. In elderly men, Verdijk et al.
[12]s h o w e dar e d u c t i o ni nt y p eI Im u s c l eﬁ b e rs a t e l l i t ec e l l
content with aging. Although various investigators support
such an age-related decrease in the number of satellite cells
[12–17], some reports [18–20] indicate no such change. In
contrast, most studies point to an age-dependent reduction
in muscle-regenerative capacity due to reduced satellite cell
proliferation and diﬀerentiation.
Several possible mechanisms for age-related muscle atro-
phy have been described; however, the precise contribution
of each is unknown. Age-related muscle loss is a result
of reductions in the size and number of muscle ﬁbers
[21] possibly due to a multifactorial process that involves
physical activity, nutritional intake, oxidative stress, and
hormonal changes [3, 22]. The speciﬁc contribution of
each of these factors is unknown, but there is emerging
evidence that the disruption of several positive regulators
(Akt and serum response factor) of muscle hypertrophy
with age is an important feature in the progression of
sarcopenia [23–25]. In contrast, many investigators have
failed to demonstrate an age-related enhancement in levels
of common negative regulators [atrophy gene-1 (Atrogin-
1), myostatin, and calpain] in senescent mammalian muscles
[24, 25].
Resistance training combined with amino acid-con-
taining supplements is eﬀective candidate to prevent age-
related muscle wasting and weakness [24–26]. In particular,
sarcopeniahasbeenmostattenuatedbytreatmentwithmany
essential amino acids plus high-amount leucine [24–26].
In addition, many researchers have focused on inhibiting
myostatin for treating various muscle disorders such as
muscular dystrophy, cachexia, and sarcopenia [27, 28].
Furthermore, more recent studies have indicated a possible
application of new supplements to prevent muscle atrophy
[29, 30]. This review aims to address several novel strategies
for inhibiting the muscle wasting in particular sarcopenia.
2. MyostatinInhibition
Growth and diﬀerentiation factor 8, otherwise known as
myostatin,wasﬁrstdiscoveredduringscreeningformembers
of a novel transforming growth factor-β (TGF-β )s u p e r f a m -
ily and shown to act as a potent negative regulator of muscle
growth [31, 32]. Studies indicate that myostatin inhibits
cell-cycle progression and levels of myogenic regulatory
factors, thereby controlling myoblastic proliferation and
diﬀerentiation during developmental myogenesis [32–35].
Mutations in myostatin can lead to massive hypertrophy
and/or hyperplasia in developing animals, as evidenced by
knockout experiments in mice and by the phenotype seen in
myostatin-null cattle [36] and humans [37]. Myostatin binds
to and signals through a combination of Activin IIA/B recep-
tors (ActRIIA/IIB) on the cell membrane; however, it has
higher aﬃnity for ActRIIB. On binding ActRIIB, myostatin
forms a complex with a second surface type I receptor, either
activin receptor-like kinase (ALK4 or ActRIB) or ALK5, to
stimulate the phosphorylation of receptor Smad (Rsmad),
and Smad2/3 transcription factors in the cytoplasm. Then
Smad2/3 translocate and modulate nuclear gene transcrip-
tion such as MyoD [33]v i aaT G F - β-like mechanism. In
contrast, forkhead box O (FOXO) 1 and Smad2 appear to
control the diﬀerentiation of C2C12 myoblasts by regulating
myostatin mRNA and its promoters [38].
Studies measuring myostatin levels during aging have
yielded conﬂicting results such as marked increases in
humans at the mRNA and protein levels [39], no change in
mice at the protein level [40], and a decrease in rats at the
mRNA level [41]. The functional role of myostatin in aged
mammalian muscle may be revealed by further descriptive
analysis using other methods (ex. immunoﬂuorescence) and
examining the adaptive changes in downstream modulators
(ex. ActRIIB, Smad3) of myostatin signaling.
Many researchers have focused on inhibiting myostatin
for treating various muscle disorders. The use of neutralizing
antibodiestomyostatinimprovedmuscledisordersinrodent
models of Duchenne muscular dystrophy (DMD), limb
girdle muscular dystrophy 2F (Sgcg−/−), and amyotrophic
lateral sclerosis (SOD1G93A transgenic mouse) [27, 28, 42,
43]. Indeed, myostatin inhibition using MYO-029 was tested
in a prospective, randomized, and US phase I/II trial in 116
adults with muscular dystrophy such as Becker muscular
dystrophy, facioscapulohumeral muscular dystrophy, and
limb-girdle muscular dystrophy [44]. On the other hand,
inhibiting myostatin to counteract sarcopenia has also been
investigated only in animals. A lack of myostatin caused
by gene manipulation increased the number of satellite
cells and enlarged the cross-sectional area of predominant
type IIB/X ﬁbers in tibialis anterior muscles of mice [45].
In addition, these myostatin-null mice showed prominent
regenerative potential including accelerated ﬁber remodeling
after an injection of notexin [45]. LeBrasseur et al. [46]
reported several positive eﬀects of 4 weeks of treatment
with PF-354 (24mg/Kg), a drug for myostatin inhibition, in
aged mice. They showed that PF-354-treated mice exhibited
signiﬁcantly greater muscle mass (by 12%), and increased
performance such as treadmill time, distance to exhaustion,
and habitual activity. Furthermore, PF-354-treated mice
exhibited decreased levels of phosphorylated Smad3 and
muscle ring-ﬁnger protein 1 (MuRF1) in aged muscle. More
recently, Murphy et al. [47] showed, by way of once weekly
injections, that a lower dose of PF-354 (10mg/Kg) signiﬁ-
cantly increased the ﬁber cross-sectional area (by 12%) and
insituforceoftibialisanteriormuscles(by35%)ofagedmice
(21-mo-old). In addition, this form of treatment reduced
markers of apoptosis by 56% and reduced caspase3 mRNA
levels by 65%. Blocking myostatin enhances muscle protein
synthesis [48] by potentially relieving the inhibition nor-
mally imposed on the Akt/mammalian target of rapamycin-
(mTOR) signaling pathway by myostatin [49]. The blockade
may also attenuate muscle protein degradation by inhibiting
the ubiquitin-proteasome system, which is controlled, in
part, by Akt [50, 51] although the mechanism involved has
not been demonstrated. In contrast, a microarray analysis of
the skeletal muscle of myostatin knockout mice showed an
increased expression of antiapoptotic genes compared withJournal of Aging Research 3
that in control mice [51]. These lines of evidence clearly
highlight the therapeutic potential of antibody-directed
inhibition of myostatin for treating sarcopenia by inhibiting
protein degradation and/or apoptosis.
3.UrsolicAcid
A water-insoluble pentacyclic triterpenoid, ursolic acid is
the major waxy component in apple peels [52]. It is also
found in many other edible plants. Interestingly, because
it exerts beneﬁcial eﬀects in animal models of diabetes
and hyperlipidemia [53, 54], ursolic acid is thought to be
the active component in a variety of folkloric antidiabetic
herbal medicines [53, 55]. As predicted by connectivity
mapping, Kunkel et al. [29] found that ursolic acid reduced
skeletalmuscleatrophyinthesettingoftwo-distinctatrophy-
inducing stresses (fasting and muscle denervation). A major
strength of the connectivity map is that it takes into account
positive and negative changes in mRNA expression that
togetherconstituteanauthenticmRNAexpressionsignature.
Thus, by querying the connective map with signatures of
muscle atrophy, Kunkel et al. [29]w e r e ,i ne ﬀect, querying
with the reciprocal signature of muscle atrophy but also
induced muscle hypertrophy.
Ursolic acid might increase muscle mass by inhibiting
atrophy-associated skeletal muscle gene expression. Indeed,
Kunkel et al. [29] found that acute ursolic acid treatment of
fasted mice reduced Atrogin-1 and MuRF1 mRNA levels in
association with reduced muscle atrophy. Similarly, chronic
ursolic acid treatment of unstressed mice reduced Atrogin-
1 and MuRF1 expression and induced muscle hypertrophy.
Although ursolic acid increased skeletal muscle Akt phos-
phorylation in vivo, the experiments could not determine
if it acted directly on skeletal muscle, how quickly it acted,
and if the eﬀect required insulin-like growth factor-I (IGF-
I) or insulin, which are always present in healthy animals,
even during fasting. To address these issues, Kunkel et al.
[29]studiedserum-starvedskeletalmyotubesandfoundthat
ursolic acid rapidly stimulated IGF-I receptor and insulin
receptoractivity,butonlyifIGF-Iorinsulinwasalsopresent.
Taken together, their data suggest that ursolic acid ﬁrst
enhances the capacity of preexisting IGF-I and insulin to
activateskeletalmuscleIGF-Ireceptorsandinsulinreceptors,
respectively. Importantly, ursolic acid alone was not suﬃ-
cient to increase phosphorylation of the IGF-I receptor or
insulin receptor. Rather, its eﬀects also required IGF-I and
insulin, respectively. This suggests that ursolic acid either
facilitates hormone-mediated receptor autophosphorylation
or inhibits receptor dephosphorylation. The latter possibility
is supported by previous in vitro data showing that ursolic
acid directly inhibits PTP1B [56], a tyrosine phosphatase
that dephosphorylates (inactivates) the IGF-I and insulin
receptors [57]. Further research is needed to elucidate the
eﬀect of supplementation with ursolic acid in skeletal muscle
and to attenuate muscle wasting (ex. sarcopenia).
4. EicosapentaenoicAcid
Eicosapentaenoic acid (EPA) is a 20-carbon omega (n)-
3 polyunsaturated fatty acid with anti-inﬂammatory
properties, which is synthesized from ingested alpha-
linolenic acid or is consumed in ﬁsh and ﬁsh oil such
as cod liver, sardine, and salmon oil [58]. There is no
established Dietary Reference Intake for n-3 fatty acids;
yet, adequate intake (AI) is set at 1.6 and 1.1g/d for men
and women, respectively. While intake in the United States
occurs at levels much lower than the proposed AI and
no signs of deﬁciency are observed, the AI is proposed to
provide optimal health beneﬁts associated with consuming
omega-3 polyunsaturated fatty acids [59]. Several clinical
trials have reported potential health beneﬁts of omega-3
polyunsaturated fatty acids in many diseases, including
cardiovascular diseases [60], epilepsy, inﬂammatory bowel
disease, exercise-trained subjects [61], and cancer-associated
cachexia [62]. In particular, the administration of omega-3
fatty acids and EPA capsules or supplements with EPA
has been shown to be associated with weight stabilization,
gains in lean body mass, and improvements in quality
of life markers in weight-losing patients with advanced
pancreatic cancer. In addition, EPA has also been shown to
inhibit the proinﬂammatory transcription factor nuclear
factor kappaB (NF-κB) [62, 63], to reduce tumor necrosis
factor-α (TNF-α) production by macrophages [64]a n d
to prevent the damaging eﬀects of TNF-α during skeletal
muscle diﬀerentiation in vitro [65]. Furthermore, short-
term treatment with EPA (16 day, 100mg/Kg) attenuates
the muscle degeneration of mdx mice, a model of DMD
[66]. EPA treatment decreased creatine kinase levels and
attenuated myonecrosis (decrease in Evans-blue dye-positive
ﬁbers and a concomitant increase in peripheral nucleated
ﬁbers), and reduced the levels of TNF-α.
Some evidence suggests omega-3 polyunsaturated fatty
acids to be also a potentially useful therapeutic agent for
the treatment and prevention of sarcopenia. In a more
recent study [30], sixteen healthy, older adults have been
randomly assigned to receive either omega-3 fatty acids or
corn oil for 8 week. In their study, the rate of muscle protein
synthesis and the phosphorylation of key elements of the
anabolic-signaling pathway were evaluated in three diﬀerent
conditions. Smith et al. [30] found that omega-3 fatty acid
supplementation had no eﬀect on the basal rate of muscle
protein synthesis but augmented the hyperaminoacidemia-
hyperinsulinemia-induced increase in the rate of muscle
proteinsynthesisprobablyduetoagreaterincreaseinmuscle
p70S6KThr389 phosphorylation.
5. Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE) inhibitors have long
been used as a treatment in primary and secondary
prevention in cardiovascular disease as well as secondary
stroke prevention. It has now been suggested that ACE
inhibitors may have a beneﬁcial eﬀect on skeletal muscle.
ACE inhibitors may exert their beneﬁcial eﬀects on skeletal
muscles through a number of diﬀerent mechanisms. ACE
inhibitors may improve muscle function through improve-
ments in endothelial function, metabolic function, anti-
inﬂammatory eﬀects, and angiogenesis thereby improving
skeletal muscle blood ﬂow. ACE inhibitors can increase4 Journal of Aging Research
mitochondrial numbers and IGF-I levels thereby helping to
counter sarcopenia [67–69].
Observational studies have shown that the long-term use
ofACEinhibitorswasassociatedwithalowerdeclineinmus-
cle strength and walking speed in older hypertensive people
and a greater lower limb lean muscle mass when compared
with users of other antihypertensive agents [70]. Several
studies have shown that ACE inhibitors improved exercise
capacity in both younger and older people with heart failure
[70, 71] but caused no improvement in grip strength [72].
Although this could be largely attributed to improvements in
cardiac function, skeletal muscle atrophy is also associated
with chronic heart failure so the evidence of muscle gains
should not be discounted. Few interventional studies using
ACE inhibitors for physical function have been undertaken.
One study looking at functionally impaired older people
without heart failure has shown that ACE inhibitors increase
6-minute walking distance to a degree comparable to that
achieved after 6 months of exercise training [73]. Another
found that ACE inhibitors increased exercise time in older
hypertensive men [74] .H o w e v e r ,as t u d yc o m p a r i n gt h e
eﬀects of nifedipine with ACE inhibitors in older people
found no diﬀerence between treatments in muscle strength,
walking distance, or functional performance [75]. It is
possible that frailer subjects with slower walking speeds,
who have a tendency to more cardiovascular problems,
beneﬁt more. Further evidence is required before recom-
mending ACE inhibitors to counter the eﬀects of sarcopenia.
However, ACE inhibitors are associated with cardiovascular
beneﬁts, and as older people frequently have underlying
cardiovascular problems, these agents are already commonly
prescribed.
6.Proteasome Inhibitors
In a variety of conditions such as cancer, diabetes, den-
ervation, uremia, sepsis, disuse, and fasting, skeletal mus-
cles undergo atrophy through degradation of myoﬁbril-
lar proteins via the ubiquitin-proteasome pathway [76].
Recent advances have asserted that muscle atrophy in these
conditions shares a common mechanism in the induction
of the muscle-speciﬁc E3 ubiquitin ligases Atrogin-1 and
MuRF1 [77–79]. Only very indirect measurements (small
increases in mRNA levels encoding some components of
the ubiquitin-proteasome pathway [80–82] or ubiquitin-
conjugate accumulation [83]) in old muscles of rodents
or humans suggested a modest activation of this pathway.
Atrogin-1 and/or MuRF1 mRNA levels in aged muscle
are reportedly unchanged in humans [83, 84], increased
in rats [80, 85], or decreased in rats [82, 86, 87]. When
even the mRNA expression of these atrogenes increased in
sarcopenic muscles, the induction was very limited (1.5–
2.5-fold) as compared with other catabolic situations (10-
fold). In addition, the major peptidase activities of the
proteasome (i.e., the chymotrypsin-like, trypsin-like, and
caspase-like activities) were always reduced (as reported in
other tissues [88]) or unchanged with aging [78, 81, 88, 89].
Altogether, these observations clearly suggest that activation
of the ubiquitin-proteasome system contributed little to the
establishment of sarcopenia in accordance with the very slow
muscle mass erosion.
There are several chemical classes of compounds that
inhibit proteasomal activity, including peptide analogs of
substrates with diﬀerent C-terminal groups, such as alde-
hydes, epoxyketones, boronic acids, and vinyl sulfones [90].
A selective boronic acid proteasome inhibitor, Velcade (also
known as PS-341 and bortezomib), directly inhibits the pro-
teasome complex without direct eﬀects on ubiquitination.
Velcade is well distributed in the body and does not cross
the blood-brain barrier. In addition to being useful research
tools for dissecting the roles of the proteasome, proteasome
inhibitors have potential applications in biotechnology and
medicine. For example, through their ability to block the
activation of NF-κB, proteasome inhibitors can dramatically
reduce in vitro and in vivo the production of inﬂammatory
mediatorsaswellasofvariousleukocyteadhesionmolecules,
which play a crucial role in many diseases. Indeed, Velcade
is orally active and is presently approved by the Food
and Drug Administration and the European Medicines
Agency and well tolerated for treating multiple myeloma
[91, 92]. Bonuccelli et al. [93] had indicated that Velcade,
once injected locally into the gastrocnemius muscles of
mdx mice, could upregulate the expression and membrane
localization of dystrophin and members of the dystrophin-
glycoprotein complex. Gazzerro et al. [94] suggested that
treatment with Velcade (0.8mg/Kg) over a 2-week period
reduced muscle degeneration and necrotic features in mdx
muscle ﬁbers, as evaluated with Evans blue dye. In addition,
they observed many myotubes and/or immature myoﬁbers
expressing embryonic myosin heavy chain in mdx muscle
after Velcade administration probably due to the upregula-
tion of several myogenic diﬀerentiating modulators (MyoD
and Myf-5). These eﬀects of Velcade on muscle degeneration
would diﬀer dependent on muscle-ﬁber type. Beehler et
al. [95]d e m o n s t r a t e ds e l e c t i v ea t t e n u a t i o no nt r e a t m e n t
with Velcade (3mg/Kg, 7 days) for atrophy of denervated
slow-type muscle (soleus), but not fast-type muscle (EDL)
of rats. In contrast, MG-132 exerts an inhibitory eﬀect
on both the proteasome and the calpain system. More
recently, Gazzerro et al. [94] have clearly demonstrated that
MG-132 increased dystrophin, alpha-sarcoglycan, and beta-
dystroglycan protein levels in explants from Becker muscular
dystrophy patients, whereas it increased the proteins of the
dystrophin glycoprotein complex in DMD cases. Strangely,
there is no rodent study examining the eﬀect of these
proteasome inhibitors to prevent muscle atrophy with aging.
As indicated previously [80, 82, 88, 89], almost no studies
demonstrated an enhancement of proteasome-linked mod-
ulators for protein degradation in sarcopenic mammalian
muscles. Proteasome inhibitors may not act to attenuate
muscle wasting in cases of sarcopenia.
7. Cyclophilin Inhibitor(Debio-025)
Ca2+ overload is known to cause cellular necrosis by directly
inducing the opening of the mitochondrial permeabilityJournal of Aging Research 5
transition (MPT) pore [96, 97]. The MPT pore spans the
inner and outer membranes of the mitochondria and, when
opened for prolonged periods of time, leads to loss of
ATP generation, swelling, rupture, and induction of cell
death [96, 97]. Cyclophilin D is a mitochondrial matrix
prolyl cis-trans isomerase that directly regulates calcium—
a n dr e a c t i v eo x y g e ns p e c i e s - d e p e n d e n tM P Ta n dc e l l u l a r
necrosis. Indeed, mice lacking Ppif (the gene-encoding
cyclophilin D) show protection from necrotic cell death in
the brain and heart after ischemic injury, and mitochondria
isolated from these mice are resistant to calcium-induced
swelling [98, 99]. Additionally, genetic deletion of Ppif
attenuatedvariousdystrophicsymptoms(ﬁberatrophy,ﬁber
loss, invasion by inﬂammatory cells, and swollen mitochon-
dria) of mice lacking δ-sarcoglycan and the α2-chain of
laminin-2 [100]. Millay et al. [100] demonstrated that the
subcutaneous injection of Debio-025, a potent inhibitor of
the cyclophilin family, improved calcium overload-induced
swelling of mitochondria and reduced manifestations of
necrotic disease such as ﬁbrosis and central nuclei, in mdx
mice, a model of DMD. In addition, treatment with Debio-
025 prevented mitochondrial dysfunction and normalized
the apoptotic rates and ultrastructural lesions of myopathic
Col6a1−/− mice, a model of human Ullrich congenital
muscular dystrophy and Bethlem myopathy [101]. More
recently, orally administered Debio-025 reduced creatine
kinase blood levels and improved grip strength in mdx mice
after 6 weeks of treatment [102]. This eﬀect on muscular
dystrophy was greater than that of prednisone, currently the
standard for treatment of DMD [103, 104]. However, it had
not been examined until now whether Debio-025 also has
a therapeutic eﬀect on the loss and/or atrophy of muscle
ﬁber with aging in rodents as well as humans. Since there are
many symptoms in common between muscular dystrophy
and sarcopenia, treatment with Debio-025 may counteract
sarcopenic symptoms.
8.PGC-1α
Although the mechanisms by which calorie restriction
(CR, 30–40%) delays the aging process remain to be fully
elucidated, CR is intricately involved in regulating cellular
and systemic redox status and in modulating the expression
of genes related to macromolecule and organelle turnover,
energy metabolism, and cell death and survival [109–
111]. Several studies indicate the protection of age-related
functional decline and loss of muscle ﬁbers by CR [109, 110].
These protective eﬀects are likely attributable to the ability
of CR to reduce the incidence of mitochondrial abnormal-
ities (mitochondrial proton leak), attenuate oxidative stress
[reactiveoxidativespecies(ROS)generation],andcounteract
the age-related increases in proapoptotic signaling in skeletal
muscle [109, 112]. Therefore, several lines of evidence sug-
gest mitochondrial involvement in sarcopenia. Therapeutic
strategies for sarcopenia like endurance exercise [113]a n d
CR [114] result in increased mitochondrial capacity in the
muscle. A key player controlling mitochondrial function is
the peroxisome proliferator-activated receptor γ coactivator
α (PGC-1α), a master regulator of mitochondrial biogenesis.
In skeletal muscle, PGC-1α can also prevent muscle wasting
by regulating autophagy [115] and stabilization of the
neuromuscular junction program [116] in the context of
muscle atrophy during disease. Thereby, PGC-1α links mito-
chondrial function to muscle integrity [115]. PGC-1α levels
in skeletal muscle decrease during aging [116]. The health-
promoting eﬀects of increased PGC-1α expression in skeletal
muscle have been shown in diﬀerent mouse models with
aﬀected muscle such as DMD [117], denervation-induced
atrophy [115], and mitochondrial myopathy [118]. Indeed,
Wenz et al. [118] showed that elevated PGC-1α expres-
sion in skeletal muscle enhanced oxidative phosphorylation
function in a mouse model of mitochondrial myopathy,
delaying theonset ofthe myopathy and markedly prolonging
lifespan.
Adipose tissue inﬁltration of skeletal muscle also in-
creases with age [119, 120]. Sarcopenia may be linked with
increased obesity in the elderly [121]. Indeed, persons who
are obese and sarcopenic are reported, independent of
age, ethnicity, smoking, and comorbidity, to have worse
outcomes, including functional impairment, disabilities, and
falls, than do those who are nonobese and sarcopenic [122].
Recent work has demonstrated that mitochondrial damage
occurs in obese individuals due to enhanced ROS and
chronic inﬂammation caused by increased fatty acid load
[123–125]. Speciﬁcally, in skeletal muscle, the expression of
PGC-1α drives not only mitochondrial biogenesis and the
establishment of oxidative myoﬁbers, but also vasculariza-
tion [126, 127]. It was found that a high-fat diet or fatty
acid treatment caused a reduction in the expression of PGC-
1α and other mitochondrial genes in skeletal muscle [128],
which may be a mechanism through which excess caloric
intake impairs skeletal muscle function. A recent study has
also demonstrated that transgenic overexpression of PGC-
1α in skeletal muscle improved sarcopenia and obesity
associated with aging in mice [129]. Endurance training has
been shown to upregulate the amount of PGC-1α to elicit
mitochondrialbiogenesis[130].Thewell-knownsarcopenia-
attenuatingeﬀectsbyendurancetrainingmaybeattributable
to the protection for mitochondrial disorders (apoptosis,
oxidative damage, etc.) by the increase of PGC-1α amount.
Figure 1 provides an overview of the molecular pathways of
muscle hypertrophy and novel strategies for counteracting
sarcopenia.
9. Conclusions and Perspectives
The advances in our understanding of muscle biology that
have occurred over the past decade have led to new hopes
for pharmacological treatment of muscle wasting. These
treatments will be tested in humans in the coming years
and oﬀer the possibility of treating sarcopenia/frailty. These
treatments should be developed in the setting of appropriate
dietary and exercise strategies. Currently, resistance training
combined with amino acid-containing supplements would
be the best way to prevent age-related muscle wasting and
weakness. Supplementation with ursolic acid and EPA seems
to be more intriguing candidates combating sarcopenia
although systematic and fundamental research in these6 Journal of Aging Research
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Figure 1: Myostatin signals through the ActRIIB-ALK4/5 heterodimer activate Smad2/3 with blocking of MyoD transactivation in an
autoregulatory feedback loop. In addition, Smad3 sequesters MyoD in the cytoplasm to prevent it from entering the nucleus and activating
the stem cell population. Recent ﬁndings [105, 106] have suggested that myostatin-Smad pathway inhibits protein synthesis probably due
to blocking the functional role of Akt. Supplementation with ursolic acid upregulates the amount of IGF-I and insulin and then stimulates
protein synthesis by activating Akt/mTOR/p70S6K pathway [29]. Treatment with ACE inhibitor also enhances IGF-I level in muscle. Amino
acid supplementation enhances protein synthesis by stimulating mTOR [107]. Akt blocks the nuclear translocation of FOXO to inhibit
the expression of Atrogin-1 and MuRF1 and the consequent protein degradation. Proteasome inhibitors combat the ubiquitin-proteasome
signaling activated by these atrogenes. In cachexic muscle, supplementation with EPA downregulates the amount of TNF-α and NF-κB
[63, 64]. Endurance exercise increases the amount of PGC-1α through calcineurin- or CaMK-dependent signaling [108]. Both activated
PGC-1α,andcyclophilininhibitorprotectsseveralmitochondrialdisorders(apoptosis,oxidativedamage,etc.)elicitedbytheincreaseinNF-
κB and Bax and/or the decrease in Bcl-2 in senescent muscle. ACE; angiotensin-converting enzyme, ActRIIB; activin receptor IIB, ALK4/5;
activin-likekinase4/5,CaMK;calmodulinkinase,eIF4E;eukaryoticinitiationfactor4E,EPA;eicosapentaenoicacid,FOXO;ForkheadboxO,
IGF-I; insulin-like growth factor-I, IKK; inhibitor of κB kinase, mTOR; mammalian target of rapamycin, MuRF1; muscle ring-ﬁnger protein
1, NF-κB; nuclear factor of kappa B, PGC-1α; peroxisome proliferator-activated receptor γ coactivator α, PI3-K; phosphatidylinositol 3-
kinase, Rheb; Ras homolog enriched in brain, TNF-α; tumor nectosis factor-α, TORC1; a component of TOR-signaling complex 1.
treatments has not been conducted even in rodent. The well-
known sarcopenia-attenuating eﬀects by endurance training
may be attributable to the protection for mitochondrial
disorders by the increase of PGC-1α amount.
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